4-(4-氯苯氧基)-苯硫醇 | 59621-76-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-氯苯氧基)-苯硫醇
• 英文名称: p-(p-Chlorphenoxy)-thiophenol
• 英文别名: 4-(4'-chlorophenoxy)thiophenol；p-(p-chlorophenoxy)-thiophenol；4-(4'-chlorophenoxy)-benzenethiol；4-(4-Chlorophenoxy)benzenethiol
• CAS: 59621-76-0
• 化学式: C₁₂H₉ClOS
• 分子量: 236.722
• InChiKey: AFXSLKKTDUYDIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  10.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯氧基)-苯硫醇 在 吡啶 、 盐酸 、 吡啶硼烷 、 盐酸羟胺 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 3-[3-[4-(4-Chlorophenoxy)phenyl]sulfanyl-2-(hydroxyamino)propyl]-5,5-dimethylimidazolidine-2,4-dione
  参考文献：
  名称：

  Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

  摘要：

  A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1' substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.

  DOI：

  10.1021/jm0103920
• 作为产物：
  描述：

  1-(4-氯苯氧基)-4-硝基苯 在 盐酸 、 氢氧化钾 、 铁粉 、 氯化铵 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 3.5h， 生成 4-(4-氯苯氧基)-苯硫醇
  参考文献：
  名称：

  Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

  摘要：

  A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1' substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.

  DOI：

  10.1021/jm0103920
• 作为试剂：
  描述：

  4-溴氯苯 、 ethyl 2-((4-hydroxyphenyl)thio)acetate 、 sodium;hydride 、 在 ice 、 氯仿 、 水 、 silica gel 、 乙酸乙酯 、 title compound 、 4-(4-氯苯氧基)-苯硫醇 、 bromo ethyl acetate 作用下， 以 吡啶 为溶剂， 反应 12.0h， 生成 [4-(4-chlorophenoxy)phenylsulfanyl]acetic acid ethyl ester
  参考文献：
  名称：

  N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

  摘要：

  基质金属蛋白酶（MMPs）是一组酶，已被证明与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括几个亚组酶，包括胶原酶、基质金属蛋白酶和明胶酶。TNF-α转化酶（TACE）是一种促炎细胞因子，它催化从膜结合的TNF-α前体蛋白形成TNF-α。因此，MMPs和TACE的小分子抑制剂有治疗多种疾病的潜力。本发明提供了低分子量、非肽类的基质金属蛋白酶（MMPs）和TNF-α转化酶（TACE）抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为1，其中R2和R3形成杂环环，A为S、S（O）或S（O）2，R1和R4如本文所定义。

  公开号：

  US20020032186A1

文献信息

• Sulphur- and oxygen-containing diaryl compounds
  申请人：Societe Anonyme dite: Laboratoire L. Lafon

  公开号：US04156011A1

  公开（公告）日：1979-05-22

  The sulphur- and oxygen-containing diaryl compounds of the formula: ##STR1## in which A and B, which may be the same or different, represent O, S, SO or SO.sub.2, Alk is a C.sub.1 -C.sub.4 hydrocarbon radical with a straight or branched chain, R represents COOH, an esterified COOH group, a carboxylic amide group, OH, O-SO.sub.2 CH.sub.3, NH.sub.2, NHR.sub.1, NR.sub.1 R.sub.2, NHZOH, NHZNR.sub.1 R.sub.2, C(.dbd.NH)NH.sub.2, C(.dbd.NH)NHOH or 2-.DELTA..sup.2 -imidazolinyl, Z is a C.sub.2 -C.sub.4 hydrocarbon radical with a straight or branched chain, and R.sub.1 and R.sub.2 each represent a C.sub.1 -C.sub.3 lower alkyl group, or together form, with the nitrogen atom to which they are linked, a N-heterocyclic group of 5 to 7 ring atoms which can be substituted and can comprise a second hetero-atom, and their addition salts with bases when R is COOH, and their addition salts with acids when R is a basic radical, are useful pharmacological agents in the treatment of circulatory complaints such as cardio-vascular illnesses.

  公式为：##STR1## 其中A和B（可以相同也可以不同）代表O、S、SO或SO.sub.2，Alk是一种直链或支链的C.sub.1-C.sub.4烃基，R代表COOH、酯化的COOH基团、羧酰胺基团、OH、O-SO.sub.2 CH.sub.3、NH.sub.2、NHR.sub.1、NR.sub.1 R.sub.2、NHZOH、NHZNR.sub.1 R.sub.2、C(.dbd.NH)NH.sub.2、C(.dbd.NH)NHOH或2-.DELTA..sup.2-咪唑啉基，Z是一种直链或支链的C.sub.2-C.sub.4烃基，R.sub.1和R.sub.2各自代表C.sub.1-C.sub.3较低的烷基基团，或者与它们连接的氮原子一起形成由5到7个环原子组成的N-杂环基团，该基团可以被取代并且可以包含第二个杂原子，当R为COOH时，它们与碱形成的加合盐，当R为碱性基团时，它们与酸形成的加合盐，在治疗心血管疾病等循环系统疾病方面是有用的药理剂。
• Reverse hydroxamate inhibitors of matrix metalloproteinases
  申请人：Abbott Laboratories

  公开号：US06294573B1

  公开（公告）日：2001-09-25

  Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

  具有以下化学式的化合物是基质金属蛋白酶抑制剂。还公开了抑制基质金属蛋白酶的组合物和方法，用于在哺乳动物中抑制基质金属蛋白酶。
• [EN] HETEROARYL RHEB INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE RHEB À BASE D'HÉTÉROARYLE ET LEURS UTILISATIONS
  申请人：NAVITOR PHARM INC

  公开号：WO2018191146A1

  公开（公告）日：2018-10-18

  The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.

  本发明提供了化合物、其组合物以及使用方法。包括本发明的化合物或其药学上可接受的衍生物与药学上可接受的载体、辅料或载体组成的组合物。本发明组合物中的化合物的量使其能够在生物样本或患者中明显抑制Rheb。
• Bicyclic hydroxamic acid derivatives
  申请人：Pfizer Inc.

  公开号：US06110964A1

  公开（公告）日：2000-08-29

  A compound of the formula ##STR1## wherein Z and Q are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use.

  其中Z和Q如规范中定义的，用于含有它们的药物组合物及其药用的公式为##STR1##的化合物。
• Methods for the treatment of liver diseases
  申请人：Spada Alfred P.

  公开号：US20080207569A1

  公开（公告）日：2008-08-28

  Provided herein are methods for treatment of a liver disease by administering a matrix metalloproteinase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the matrix metalloproteinase inhibitor described herein. Further provided are methods for lowering an elevated level of liver enzymes by administering the matrix metalloproteinase inhibitor.

  本文提供了一种通过给予基质金属蛋白酶抑制剂治疗肝病的方法。还提供了一种通过给予本文描述的基质金属蛋白酶抑制剂来减少与肝病相关的肝损伤的方法。此外，还提供了一种通过给予基质金属蛋白酶抑制剂来降低肝酶升高水平的方法。